REG - Theracryf PLC - Notice of Results

TheracryfAnnouncement

24/11/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251124:nRSX6294Ia&default-theme=true

RNS Number : 6294I  Theracryf PLC  24 November 2025

 

TheraCryf plc

("TheraCryf", the "Company" or the "Group")

 

Notice of Half Year results

 

Alderley Park, 24 November 2025 - TheraCryf plc (AIM: TCF), the clinical
stage drug development company focussing on neuropsychiatry and
oncology, announces that the Company's half year results for the six months
to 30 September 2025 will be released on Wednesday, 3 December 2025.

 

A live presentation of the results will be given at 11am GMT on 3 December,
via Investor Meet Company
(https://www.investormeetcompany.com/theracryf-plc/register-investor) by Dr
Huw Jones, CEO, Toni Hänninen, CFO and Dr Helen Kuhlman, COO.

 

The results presentation will be open to all existing and potential
shareholders. Questions can be submitted up to 24 hours prior to either event
via the Investor Meet Company dashboard or during the live presentations.

 

Investors who already follow TheraCryf plc on the Investor Meet Company
platform will automatically be invited. New registrants can sign up to
Investor Meet Company HERE
(https://www.investormeetcompany.com/theracryf-plc/register-investor) .

 

-Ends-

Enquiries

 TheraCryf plc                                       +44 (0)1625 315 090

 Dr Huw Jones, CEO                                   enquiries@theracryf.com

 Toni Hänninen, CFO

 Dr Helen Kuhlman, COO

 Singer Capital Markets (NOMAD & Joint Broker)       +44 (0)20 7496 3000
 Phil Davies / Oliver Platts / Patrick Weaver

 Turner Pope Investments (Joint Broker)              +44 (0)20 3657 0050

 James Pope / Andy Thacker

 Vigo Consulting                                     +44 (0)20 7390 0230

 Rozi Morris/ Melanie Toyne Sewell                   theracryf@vigoconsulting.com

About TheraCryf plc

TheraCryf is the clinical stage drug development company focussing on brain
disorders. The Company has a broad clinical and preclinical pipeline in
indications including addiction, anxiety, fatigue, narcolepsy, glioblastoma*
and neurodevelopmental disorders [*orphan indication].

 

The Company's strategy is to generate compelling data sets to preclinical
and/or clinical proof of concept and partner its clinical programmes with
mid-size to large pharma for larger trials and commercialisation. It also has
a number of industry partnerships with companies, including Stalicla SA, in
neurodevelopmental disorders.  The Company has sourced know-how for
programmes from companies such as Shire (now Takeda).

 

TheraCryf has worked with and has ongoing collaborations with major
universities and hospitals such as the University of Manchester, La Sapienza
(Università di Roma), the Erasmus Medical Centre, Rotterdam, Kings College
London and the University of Michigan.

 

The Company has its headquarters and registered office at Alderley
Park, Cheshire. It is quoted on AIM in London and trades under the
ticker symbol TCF. 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NORBJBFTMTITBMA



            Copyright 2019 Regulatory News Service, all rights reserved